SNMMI’s 63rd Annual Meeting Highlights History of FDG and Showcases New Research

June 16, 2016

Reston, Va. (June 15, 2016) — More than 5,700 physicians, technologists, scientists and exhibitors gathered at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2016 Annual Meeting, held June 11-15 in San Diego, Calif.

This year’s meeting included a celebration of the 40th anniversary of FDG. At the opening plenary, the Henry Wagner Lecture was given by Joanna Fowler, PhD, Brookhaven National Laboratory, on “Designing and Synthesizing FDG for the First Human Studies in 1976.” A short video illustrated the pervasive impact of FDG and celebrated those involved in its development. Signage throughout the convention center featured FDG pioneers and quotes on FDG by past presidents.

SNMMI also launched a new “Highlight Country” program. The first country to be featured was Japan, with significant contributions to the meeting and to the field of nuclear medicine and molecular imaging. The president of the Japanese Society of Nuclear Medicine, Jun Hatazawa, MD, PhD, gave a presentation on the state of nuclear medicine in Japan. In addition, top abstracts for each of 50 countries participating in the meeting were recognized with awards.

SNMMI launched a new fellowship program at the Sunday plenary to recognize distinguished service to SNMMI, as well as exceptional achievement in the field of nuclear medicine and molecular imaging. The Fellowship is recognized with the designation FSNMMI.

The 2016 Image of the Year was awarded to a German team of researchers from the University Hospital of Cologne; the Jülich Research Center; and the German Center for Neurodegenerative Diseases. Measuring tau deposits using the novel radiotracer 18F-AV-1451 (18F-T807), in conjunction with 11C-PiB to measure amyloid plaques and 18F-FDG to measure regional neurodegeneration, offers new insight into the neurodegenerative characteristics of Alzheimer’s disease and shows that tau pathology may be an instrumental target for disease-modifying strategies.

SNMMI again held a Patient Program at the annual meeting. More than 100 patients and caregivers attended sessions on advances in nuclear medicine and molecular imaging. Topics featured included prostate cancer, breast cancer and neuroendocrine tumors. 

SNMMI is offering a Virtual Meeting for those who were unable to attend certain sessions or make the trip to San Diego. It will cover 100 sessions, and 50 will offer CE credit. For the first, a Virtual Poster Hall will also be offered and will open on June 30.

The SNMMI 2017 Annual Meeting will take place June 10–14 in Denver, Colo. For more information, visit 



About the Society of Nuclear Medicine and Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising public awareness about nuclear medicine and molecular imaging, a vital element of today’s medical practice that adds an additional dimension to diagnosis, changing the way common and devastating diseases are understood and treated and helping provide patients with the best health care possible.

SNMMI’s more than 17,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit